Latest news with #AAV
New York Post
11 hours ago
- Sport
- New York Post
Mathieu Darche adroitly avoided sentiment in important first Islanders draft
It's just unfortunate that Jeff Gorton didn't want Noah Dobson this badly seven years ago — or even at all — when, as the Rangers general manager, he could have selected the righty defenseman at ninth overall in the first round instead of choosing Vitali Kravtsov at the 2018 draft in Dallas. But no. But, fast-forwarding to Friday in his current position as Montreal's executive VP of hockey operations, Gorton oversaw the trade for Dobson by sending the Islanders the 16th and 17th selections in the first round plus winger Emil Heineman after the defenseman agreed to an eight-year extension at a $9.5 million AAV. Advertisement The deal, completed early in the day, makes a whole lot of sense for the Canadiens all day and every day.
Time of India
18 hours ago
- Sport
- Time of India
NHL Trade Rumors: Insider drops hint Aaron Ekblad may soon be playing for Columbus blue jackets
NHL Trade Rumors: Insider drops hint Aaron Ekblad may soon be playing for Columbus blue jackets (Image via getty) An interesting trade might be coming for Aaron Ekblad. On the latest DFO Rundown, NHL insider Frank Seravalli hinted that the Florida Panthers star defenseman 'could end up in Columbus. ' The idea has fans talking and raises big questions about Ekblad's next move. Aaron Ekblad linked to Columbus by Frank Seravalli On June 26, 2025, Frank Seravalli spoke during the Daily Faceoff Rundown that Aaron Ekblad 'could end up in Columbus.' Ekblad, 29, is a top‑four right‑shot defenseman and as a two‑time Stanley Cup winner, he remains a hot prospect. With Ekblad's contract likely to expire July 1, Seravalli said multiple teams are watching him closely, including the Columbus Blue Jackets. The Jackets currently have around $40 million in cap space, which gives them room to make a major signing or trade in free agency . Ekblad spent his entire NHL career with the Florida Panthers since being the first overall pick in 2014. Last season he scored 33 points in 56 games and helped lead Florida to back‑to‑back Stanley Cup wins in 2024 and 2025 (). He missed 20 games recently due to a PED suspension, but remains highly regarded for his size, skill, and experience . by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like After Losing Weight Kevin James Looks Like A Model 33 Bridges Undo Aaron Ekblad deal talk sparks debate over long term fit Talk of Ekblad possibly ending up in Columbus has stirred conversation among fans and experts. Some believe his offensive game and championship pedigree would boost the Blue Jackets' defence. Others worry about his $7.8 million AAV cap hit and potential injury history. Scott Wheeler of The Athletic flagged Ekblad as likely headed to free agency and noted the Panthers may struggle to match his expected value. Meanwhile, Sports Journalist Cole Shelton at said, 'I think everyone has spent a lot of time wondering what Aaron Ekblad might look like in a Toronto Maple Leafs uniform,' s howing how multiple teams are weighing in. Also Read: NHL Trade Rumors: Connor McDavid Not Expected To Commit Long Term To Oilers After 2026 With Ekblad's no‑trade protection ending in July and Columbus holding enough space to make a strong offer, this could be one of the most watched free agent signings of the summer. If it happens, it would make a big splash for both Ekblad's future and Columbus's defense lineup. Game On Season 1 continues with Mirabai Chanu's inspiring story. Watch Episode 2 here.
Edmonton Journal
19 hours ago
- Sport
- Edmonton Journal
Dobson deal could be template for Oilers D Evan Bouchard extension
Article content That $9.5-million AAV deal that Noah Dobson signed in Montreal after his New York Islanders' trade might be a template for Evan Bouchard's Edmonton Oilers ' contract negotiation. Not sure Bouchard wants to sign here for eight years as Dobson did with the Habs — the feeling is he might want shorter, say, four years, to see where the salary cap goes — but these are similar, offensive-minded defencemen. Same right-shot, same age, 25, same draft year in 2018. Bouchard went 10th, Dobson 12th.
Yahoo
20 hours ago
- Sport
- Yahoo
Noah Dobson trade grades: Who won the Islanders and Canadiens deal?
We have a big pre-NHL draft trade that was discussed a bunch on Friday as we get ready for the 2025 edition of the draft: the New York Islanders sent defenseman Noah Dobson (a homegrown stud who was the 12th overall pick in 2018) to the Montreal Canadiens, who are getting another good D-man to add to their blue line that has Calder Trophy winner Lane Hutson. This made sense for the Islanders if they weren't giving Dobson a long-term deal given that he was a pending restricted free agent. For the Canadiens? They're taking steps in the right direction for their rebuild. Advertisement As we do around here, let's hand out some grades to each team for this one: Canadiens and Islanders trade details: CANADIENS GET: D Noah Dobson (who got an 8-year contract with an AAV of $9.5 million) ISLANDERS GET: F Emil Heineman, the 16th and 17th overall picks in the 2025 NHL draft Islanders trade grade Dobson is seriously talented, even if his points dipped last season. But if the Islanders weren't re-signing him to a long-term deal, it made sense to deal him. And this haul? It's pretty darn good: TWO first-rounders and Heineman, who was a 2020 second-rounder. He scored 10 goals in his first full-time season last year, and maybe there's more untapped potential here for a 23-year-old with that draft pedigree. Advertisement If you have to deal a top-tier defenseman, this is the kind of return you should get back. It's just a bummer for a team that could use him as they try to get back to the postseason. GRADE: B+ Canadiens trade grade Montreal is on the rise, with their first stop in the playoffs since 2021. And Dobson will anchor the blue line with Hutson for years, which is a formidable pairing. That said, giving up two first-rounders and a former second-round forward is A LOT, plus the giant extension. But that's the price you pay for a talent like Dobson and for moving toward contention. GRADE: B This article originally appeared on For The Win: Noah Dobson trade grades for Islanders and Canadiens deal
Malaysian Reserve
a day ago
- Business
- Malaysian Reserve
ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility in Hopewell, New Jersey to Advance Cell and Gene Therapy
HOPEWELL, N.J., June 27, 2025 /PRNewswire/ — ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced the opening of its flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell, New Jersey. The 128,000 sq ft GMP facility is purpose-built for manufacturing high-quality plasmid DNA and viral vectors, including adeno-associated virus (AAV) and lentiviral vector (LVV) platforms, reflecting ProBio's dedication to accelerating the delivery of transformative medicines. The celebration included an open house event featuring a guided site tour, ribbon-cutting ceremony, and a keynote address by Donavon Decker, the first person in the world to receive gene therapy for any form of muscular dystrophy in 1999. Decker shared his experience from that landmark trial at Ohio State University—led by Dr. Jerry Mendell—and spoke movingly about how state-of-the-art facilities like ProBio's Hopewell site help translate scientific advances into real patient outcomes. The ribbon-cutting ceremony featured remarks from prominent leaders: Debbie Hart, CEO of BioNJ; Courtney Peters–Manning, Mayor of Hopewell Township; John Coelho of the New Jersey Economic Development Authority (NJEDA); Michael Vreeland, Site Head of ProBio Hopewell; Allen Guo, CEO of ProBio; and Frank Zhang, Founder of GenScript and Chairman of Legend Biotech. Mayor Courtney Peters-Manning welcomed the company warmly, stating: 'Hopewell Township is a wonderful place to live and work, and we are thrilled to welcome ProBio to our community, where they will make cutting-edge, life-changing therapies, in addition to creating high-skilled jobs.' John Coelho of NJEDA emphasized the strategic significance of the opening: 'The opening of ProBio, a state-of-the-art fully integrated end-to-end Contract Development and Manufacturing Organization, will be a significant enhancement to the cell and gene biologics development and biomanufacturing ecosystem, anchoring New Jersey as a leader in the field. The potential to support production for global clinical trial registrations and close proximity to leading precision medical centers will enable faster access of breakthrough medicines to patients.' Built to meet the most rigorous GMP standards, the Hopewell site is equipped to support clinical-stage development, process-development and scale-up for cell and gene therapy programs. This capability solidifies New Jersey's position as a leader in biopharmaceutical manufacturing. During the open house, guests toured advanced GMP suites and production lines, and engaged with ProBio's scientific and operations teams as well as industry, academic, and government partners. 'This is not just a new facility. It is a beacon of hope for patients waiting for cures,' said Allen Guo, CEO of ProBio. 'Opening the Hopewell center is a milestone in ProBio's global expansion and underscores our mission to support biopharma innovators with high-quality, responsive manufacturing solutions.' Bringing over 110 high-skilled jobs to New Jersey, ProBio's Hopewell facility continues to expand its capabilities. GMP AAV manufacturing is set to launch by Q3 2025, with GMP LVV services to follow in Q1 2026—enabling support for a broader range of therapeutic candidates from early proof-of-concept through clinical readiness, all within one integrated site. Located in the heart of New Jersey's rapidly expanding innovation corridor, ProBio's Hopewell facility serves as the company's North American hub, designed to support and complement its broader operations across North America and Europe. This strategic investment aligns with efforts to strengthen transatlantic biomanufacturing capacity and resilience—positioning the site to meet growing demand for advanced therapeutic production across both continents. For more information about ProBio and its full suite of development and manufacturing services, please visit ABOUT PROBIO ProBio is a global leader in advancing the development and manufacturing of next generation biologics and advanced therapies for the biotech and pharmaceutical industries. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio partners with its clients to optimize drug development, accelerate time-to-market, and provide comprehensive life-cycle support. Through a collaborative, risk-sharing approach, ProBio offers flexible licensing and co-development options for new therapeutics, enabling partners to effectively navigate the complexities of human disease with adaptable, cutting-edge therapeutic approaches. To learn more about ProBio services, please visit CUSTOMIZED CDMO SOLUTIONS. DEVELOPED FASTER. DELIVERED BETTER. Media Contact:Alvin Jogasuria Head of Marketing, Americas and Europe[email protected]
